Clinical trials: Gefitinib
Cancer
Open-Label Extension of Other SZ1839 (Iressa) Trials
A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.
- Trial name
- NCT00635973
- Testing
- Gefitinib (Iressa)
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Phase II Iressa & Carbo/Gem in NSCLC
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
- Trial name
- NCT00264498
- Testing
- Gefitinib, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Cancer
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
The investigators performed a multi-centered, randomized, double blinded, placebo-controlled, prospective clinical trial on the effect of Yiqi-yangyin-jiedu decoction (YYJD), a chinese herbal medicine (CHM) formula combined with…
- Trial name
- NCT02929693
- Testing
- gefitinib, Yiqi-yangyin-jiedu decoction
- Volunteers
- 198 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Colorectal Cancer
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth…
- Trial name
- NCT00026299
- Testing
- ZD1839, oxaliplatin
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Chicago
NSCLC
Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients
Currently, whether adjuvant therapy should be applied to Stage Ib non-small cell lung cancer (NSCLC) patients who received radical resection remains controversial.
- Trial name
- NCT02526537
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lunxu Liu
Lung Cancer
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898924
- Testing
- molecular diagnostic method, mutation analysis
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
NSCLC
Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy
The study aims to randomize 52 patients with advanced (Stage IV) EGFR mutation negative nonsquamous non-small cell lung cancer (NSCLC) who respond (CR/PR/SD) to 4 cycles of pemetrexed / cisplatin or pemetrexed/carboplatin as…
- Trial name
- NCT01579630
- Testing
- Pemetrexed 500mg/m2 iv, Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Gefitinib in Treating Patients With Malignant Mesothelioma
Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant…
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00025207
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
- Trial name
- NCT02179671
- Testing
- Gefitinib, AZD9291, Selumetinib+Docetaxel
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
This is an open-label phase 1, safety, PK, and preliminary efficacy study of oral Gefitinib and IV Tremelimumab in previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have…
- Trial name
- GEFTREM (NCT02040064)
- Testing
- Gefitinib, Tremelimumab
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-Small-Cell Lung
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
After the second-line treatment of patients with non-T790M mutations, chemotherapy with platinum-containing drugs was used, and chemotherapy-related toxicity was high.
- Trial name
- NCT03766490
- Testing
- Anlotinib Hydrochloride, Gefitinib, Icotinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients.
- Trial name
- NCT04390984
- Testing
- Apatinib Mesylate, Gefitinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of SH-1028 tablets versus Gefitinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor, in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT04239833
- Testing
- SH-1028 tablets, Gefitinib
- Volunteers
- 240 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Non-small Cell Lung Cancer
the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)
1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability of comparative studies which examine people in vivo…
- Trial name
- NCT03264794
- Testing
- Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial, Gefitinib tablets (Yi Ruisha），First medication, Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
- Volunteers
- 100 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Breast Cancer
IRESSA™ (Gefitinib) in Breast Cancer Patients
This is a phase II trial to assess whether IRESSA™ (gefitinib) has anti-tumour efficacy in patients with breast cancer. The trial proposes to enter 27 patients who have acquired resistance to tamoxifen and 27 patients with ER…
- Trial name
- NCT00632723
- Testing
- gefitinib (IRESSA™, ZD1839)
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Lung Cancer
A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer
A randomized phase III trial of platinum-based chemotherapy alone versus platinum-based chemotherapy followed by maintenance therapy with gefitinib in patients with stage IIIB/IV NSCLC.
- Trial name
- NCT00144066
- Testing
- platinum-based chemotherapy alone (up to six cycles), platinum-based chemotherapy followed by maintenance therapy with gefitinib
- Volunteers
- 600 people
- Sponsor
- West Japan Thoracic Oncology Group
Cancer
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
This is a phase II, open-label trial of Gefitinib and docetaxel in patients having one prior regimen of chemotherapy for with metastatic pancreatic carcinoma.
- Trial name
- NCT00177242
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Pittsburgh
Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?
Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?
Not significantly increased survival in T/T
- Trial name
- NCT02740894
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Lung Cancer
NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.
The purpose of this study is to studying neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib to see how well it works in treating patients with unresectable stage III NSCLC harboring EGFR mutations.
- Trial name
- NEGOTIATE (NCT02347839)
- Testing
- Gefitinib-surgery-gefitinib
- Where
- China
- Sponsor
- Sun Yat-sen University